54 results
6-K
EX-99.1
AMYT
Amryt Pharma Plc
3 Nov 22
Current report (foreign)
7:44am
EXHIBIT 99.1
Amryt Receives Reimbursement Approval from the Dutch Ministry of Health for Myalepta® (metreleptin)
DUBLIN, Ireland, and Boston MA … novel treatments for rare diseases, announces that the Dutch Ministry of Health has approved Myalepta® (metreleptin) for reimbursement in the Netherlands
6-K
EX-99.7
AMYT
Amryt Pharma Plc
3 Nov 22
Current report (foreign)
7:44am
on a constant currency basis during Q3 would have been 13.8% YoY.
EMEA growth drivers include reimbursement for partial lipodystrophy (PL) in Italy … , general lipodystrophy (GL) in the Netherlands and a strong performance in Turkey and the Middle East
Reimbursement processes are also being progressed
6-K
EX-99.5
AMYT
Amryt Pharma Plc
4 Aug 22
Results of Annual General Meeting
7:38am
general and partial lipodystrophy (GL/PL)
Growth drivers include Italian PL reimbursement in Q2 and expansion in the Middle East and Turkey
Metreleptin
424B3
mp1m3n
9 Mar 22
Prospectus supplement
9:26am
424B3
nq7zu 2nhvo
9 Mar 22
Prospectus supplement
9:25am
6-K
EX-99.1
2wimsmy0t
9 Mar 22
Amryt Announces 22% growth in FY 2021 Revenues to $222.5M
9:23am
6-K
EX-99.1
8cazz9ggke 9x0xp968
25 Feb 22
Current report (foreign)
4:05pm
424B3
gmvvogj ir
1 Jul 21
Prospectus supplement
5:20pm
F-4/A
3xfyq7pfdj v53r
29 Jun 21
Registration of securities (foreign) (amended)
9:29am
F-4
6mi p87qvk7
15 Jun 21
Registration of securities (foreign)
12:00am
424B3
omnc5g3hlpxxw4iyv1
2 Jun 21
Prospectus supplement
10:10am
424B3
bdos5b
2 Jun 21
Prospectus supplement
10:09am
424B3
4u1620d e5c4ca7a
2 Jun 21
Prospectus supplement
10:08am
425
vmlt y46oq5kxs640ci
5 May 21
Business combination disclosure
5:27pm
6-K
EX-99.1
9hs8ixtngg
5 May 21
Amryt Reports Record Q1 2021 Financial and Operating Results
9:40am